Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients.
FRIDAY, Aug. 19, 2022 (HealthDay News) Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA) and non-AA patients, according to a study published online July 29 in Clinical Cancer Research. Julia Foldi, M.D.,
Findings from a new study led by Yale Cancer Center show the small molecule inhibitor drug, PF05175157, originally developed to treat diabetes by Pfizer, may help in the treatment of breast cancer.